Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07509645 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke

Study acronym: IRIS-3
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 13 → 30 locations
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 1 of 8 entries
  2. Secondary endpoints revised (8)v5
  3. Trial sites expanded: 6 → 13 locations
    • Start date changed from estimate of Apr 20, 2026 to Apr 22, 2026
    v4
  4. Recruitment opened
    • Trial sites expanded: 1 → 6 locations
    v3
  5. Primary and study completion dates: Apr 10, 2027 to Apr 20, 2027
    • Start date: Apr 10, 2026 to Apr 20, 2026
    • Secondary endpoints: details revised at 1 of 8 entries
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an investigator-initiated phase III clinical trial employing a randomized, double-blind, placebo-controlled design. The primary objective of this study is to investigate the efficacy and safety of an interleukin-6 inhibitor (tocilizumab) combined with endovascular therapy in patients with acute posterior circulation large-vessel occlusion stroke.
Trial Details
NCT Number NCT07509645
Lead Sponsor Capital Medical University
Conditions
(from sponsor)		 Ischemic Stroke
Related terms Ischemic Stroke
Enrollment 348 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov